Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells

BACKGROUND: In addition to the mutational status of KRAS, the epidermal growth factor receptor (EGFR) ligands amphiregulin (AREG) and epiregulin (EREG) might function as bona fide biomarkers of cetuximab (Ctx) sensitivity for most EGFR-driven carcinomas. METHODS: Lentivirus-delivered small hairpin R...

Descripción completa

Detalles Bibliográficos
Autores principales: Oliveras-Ferraros, C, Cufí, S, Queralt, B, Vazquez-Martin, A, Martin-Castillo, B, de Llorens, R, Bosch-Barrera, J, Brunet, J, Menendez, J A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3326676/
https://www.ncbi.nlm.nih.gov/pubmed/22491422
http://dx.doi.org/10.1038/bjc.2012.103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3326676/
https://www.ncbi.nlm.nih.gov/pubmed/22491422
http://dx.doi.org/10.1038/bjc.2012.103

Ejemplares similares